Induction of Pluripotent Stem Cells From Human Fibroblasts of DM1 Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-30

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is the modelisation of human cardiomyocyts from pluripotent stem cells in order to study the cardiac alterations induced by CTG expansions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Generation of Marfan Syndrome and Fontan Cardiovascular Models Using Patient-specific Induced Pluripotent Stem Cells

NCT02815072

Marfan's Syndrome

UNKNOWN

In Vivo Tracking of USPIO Labeled MSC in the Heart

NCT03651791

Ischemic Heart Disease

COMPLETED PHASE1

Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.

NCT00102128

Ischemic Heart Failure Ischemic Heart Disease Ischemic Cardiomyopathy

TERMINATED PHASE2

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF

NCT05016817

Idiopathic Pulmonary Fibrosis

RECRUITING PHASE1

Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy

NCT01957826

Primary Idiopathic Dilated Cardiomyopathy

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

DM1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DM1 subject with cardiopathy

Clinical examination, Skin biopsy, Blood and urine sampling

Group Type ACTIVE_COMPARATOR

Clinical examination, skin biopsy, blood and urine sampling

Intervention Type OTHER

DM1 subject without cardiopathy

Clinical examination, Skin biopsy, Blood and urine sampling

Group Type ACTIVE_COMPARATOR

Clinical examination, skin biopsy, blood and urine sampling

Intervention Type OTHER

Not DM1subject

Clinical examination, Skin biopsy, Blood and urine sampling

Group Type ACTIVE_COMPARATOR

Clinical examination, skin biopsy, blood and urine sampling

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinical examination, skin biopsy, blood and urine sampling

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* aged 20-50
* DM1 confirmed by molecular analysis
* Confirmed cardiomyopathy (infrahissiens conduction disorders)
* able to sign the consent form
* affiliated to european social security.

* aged 20-50
* DM1 confirmed by molecular analysis
* No cardiomyopathy (no infrahissiens conduction disorders or other trouble linked to DM1)
* able to sign the consent form
* affiliated to european social security.

* aged over 18
* brother, sister, father or mother of the DM1 patient
* No DM1 confirmed by molecular analysis (CTG repetition under 38)
* No cardiac disorders.
* able to sign the consent form
* affiliated to european social security.